Antigens, CD80

• 

  Subject Areas on Research

  • A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. 
  • B Cell Subsets Differentially Contribute to the T Cell-Independent Memory Pool. 
  • B cell antigen receptor endocytosis and antigen presentation to T cells require Vav and dynamin. 
  • CD7 and CD28 are required for murine CD4+CD25+ regulatory T cell homeostasis and prevention of thyroiditis. 
  • CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. 
  • Cell-based vaccines for the stimulation of immunity to metastatic cancers. 
  • Cellular FLIP Inhibits Myeloid Cell Activation by Suppressing Selective Innate Signaling. 
  • Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. 
  • Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation. 
  • Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. 
  • Comparison of thymocyte development and cytokine production in CD7-deficient, CD28-deficient and CD7/CD28 double-deficient mice. 
  • Costimulation, coinhibition and cancer. 
  • Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice. 
  • Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. 
  • Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. 
  • Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. 
  • Endothelial antigen presentation: stimulation of previously activated but not naïve TCR-transgenic mouse T cells. 
  • Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. 
  • Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium. 
  • Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. 
  • Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. 
  • Identifying regulatory B cells (B10 cells) that produce IL-10 in mice. 
  • Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. 
  • Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. 
  • Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. 
  • Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. 
  • Inherited variants in regulatory T cell genes and outcome of ovarian cancer. 
  • Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. 
  • Non-erythroid effects of erythropoietin. 
  • Optimizing dendritic cell function by genetic modification. 
  • Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma. 
  • PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. 
  • Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. 
  • Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. 
  • Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. 
  • Porcine CD80: cloning, characterization, and evidence for its role in direct human T-cell activation. 
  • Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. 
  • Renal epithelial cell-derived monocyte colony stimulating factor as a local informant of renal injury and means of monocyte activation. 
  • Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. 
  • Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 
  • Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. 
  • Tgf-beta inhibits activation and uveitogenicity of primary but not of fully polarized retinal antigen-specific memory-effector T cells. 
  • The B7-2 (B70) costimulatory molecule expressed by monocytes and activated B lymphocytes is the CD86 differentiation antigen. 
  • The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. 
  • Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. 
  • Tumor cells cotransduced with B7.1 and gamma-IFN induce effective rejection of established parental tumor. 
  • Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology